NDOI Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -32.74% compared to Endo's net margin of --. Endo's return on equity of -- beat Nanoviricides's return on equity of --.

Endo has a consensus price target of $40.00, signalling upside risk potential of 91.39%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 330.46%. Given that Nanoviricides has higher upside potential than Endo, analysts believe Nanoviricides is more attractive than Endo.

Endo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

Endo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Endo pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Endo quarterly revenues are $392.8M, which are larger than Nanoviricides quarterly revenues of --. Endo's net income of -$128.6M is lower than Nanoviricides's net income of -$2.2M. Notably, Endo's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Endo is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -32.74% compared to Endo's net margin of --. Endo's return on equity of -- beat Oragenics's return on equity of --.

Endo has a consensus price target of $40.00, signalling upside risk potential of 91.39%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 548.01%. Given that Oragenics has higher upside potential than Endo, analysts believe Oragenics is more attractive than Endo.

Endo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Endo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Endo pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Endo quarterly revenues are $392.8M, which are larger than Oragenics quarterly revenues of --. Endo's net income of -$128.6M is lower than Oragenics's net income of -$2.2M. Notably, Endo's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Endo is -- versus 1.48x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Reshape Lifesciences has a net margin of -32.74% compared to Endo's net margin of -68.98%. Endo's return on equity of -- beat Reshape Lifesciences's return on equity of -172.58%.

Endo has a consensus price target of $40.00, signalling upside risk potential of 91.39%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 46523.74%. Given that Reshape Lifesciences has higher upside potential than Endo, analysts believe Reshape Lifesciences is more attractive than Endo.

Endo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.358%.

Endo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Endo pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

Endo quarterly revenues are $392.8M, which are larger than Reshape Lifesciences quarterly revenues of $1.1M. Endo's net income of -$128.6M is lower than Reshape Lifesciences's net income of $1.5M. Notably, Endo's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is 0.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Endo is -- versus 0.01x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -32.74% compared to Endo's net margin of --. Endo's return on equity of -- beat Theriva Biologics's return on equity of --.

Endo has a consensus price target of $40.00, signalling upside risk potential of 91.39%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1301.12%. Given that Theriva Biologics has higher upside potential than Endo, analysts believe Theriva Biologics is more attractive than Endo.

Endo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Endo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Endo pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Endo quarterly revenues are $392.8M, which are larger than Theriva Biologics quarterly revenues of --. Endo's net income of -$128.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Endo's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Endo is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.